Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
9358 participants
INTERVENTIONAL
1996-07-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ATAC - Pharmacokinetics (PK) Sub-Protocol
NCT00784862
ATAC - Endometrial Sub-Protocol
NCT00814125
ATAC - Quality of Life Sub-Protocol
NCT00784680
ATAC - Bone Density Sub-Protocol
NCT00784940
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
NCT00287534
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Arimidex 1mg + Nolvadex placebo
Anastozole (Arimidex)
1mg, orally, once daily
Tamoxifen (Nolvadex) placebo
20mg, orally, once daily
2
Arimidex placebo + Nolvadex 20mg
Tamoxifen (Nolvadex)
20mg, orally, once daily
Anastozole (Arimidex) placebo
1mg, orally, once daily
3
Arimidex 1mg + Nolvadex 20mg
Anastozole (Arimidex)
1mg, orally, once daily
Tamoxifen (Nolvadex)
20mg, orally, once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anastozole (Arimidex)
1mg, orally, once daily
Tamoxifen (Nolvadex)
20mg, orally, once daily
Anastozole (Arimidex) placebo
1mg, orally, once daily
Tamoxifen (Nolvadex) placebo
20mg, orally, once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have completed all primary surgery and chemotherapy (if given), and are candidates to receive hormonal adjuvant therapy
* Women defined as post-menopausal
Exclusion Criteria
* Patients who, for whatever reason (e.g. confusion, infirmity, alcoholism), are unlikely to comply with trial requirements
* Patients whose chemotherapy was started more than 8 weeks (ie 56 days) after completion of primary surgery or whose chemotherapy was completed more than 8 weeks (ie 56 days) before starting randomised treatment
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5392C00029
Identifier Type: -
Identifier Source: secondary_id
1033IL/0029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.